Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

House Committee To Consider National Rx Drug Monitoring Bill Sept. 30

This article was originally published in The Pink Sheet Daily

Executive Summary

The “National All Schedules Prescription Electronic Reporting Act” would create a nationwide monitoring system. Thirty-one states currently have monitoring programs or are working to create them, but the state-centered systems are “inherently flawed” because they do not reach across state lines, the bill’s sponsor says.

You may also be interested in...



House Passes Rx Abuse Monitoring Bill

Compromise legislation on prescription drug abuse monitoring systems passed the House in a voice vote Oct. 5.

House Passes Rx Abuse Monitoring Bill

Compromise legislation on prescription drug abuse monitoring systems passed the House in a voice vote Oct. 5.

Compromise House Rx Abuse Monitoring Bill Moves Away From National Database

The bill would establish HHS grants for state databases. The compromise bill could be ready for House floor action in days, committee members say.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS060661

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel